[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598582":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":43,"collaborators":19,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Pusan National University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Local Therapy Arm","EXPERIMENTAL","Patients with EGFR-mutant advanced non-small cell lung cancer who achieve disease control after first-line osimertinib plus chemotherapy (FLAURA2 regimen) will receive local therapy (surgery or radiotherapy) to the primary tumor. The study will evaluate clinical outcomes including progression-free survival, overall survival, and treatment-related toxicity.",[13],"Other: Local Therapy (Surgery or Radiotherapy)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Local Therapy (Surgery or Radiotherapy)","Patients will receive local therapy, either surgical resection or radiotherapy, to the primary lung tumor following disease control after first-line treatment with osimertinib plus platinum-based chemotherapy (FLAURA2 regimen). The specific modality (surgery or radiotherapy) will be determined based on tumor characteristics, patient condition, and multidisciplinary team assessment.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Mi-Hyun Kim","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","82-51-240-7845","mihyunkim@pusan.ac.kr",{"name":30,"role":26,"phone":27,"phoneExt":19,"email":31},"Soo Han Kim","kshyjt1004@gmail.com",[33],{"facility":5,"status":34,"city":35,"state":19,"zip":19,"country":36,"countryCode":19,"cosmosGeoPoint":37,"geoPoint":42,"contacts":19},"RECRUITING","Busan","South Korea",{"type":38,"coordinates":39},"Point",[40,41],129.03004,35.10168,{"lat":41,"lon":40},{"type":44,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100598582","phase-2-bolstering-outcomes-after-induction-with-osimertinib-plus-chemotherapy-through-optimized-site-directed-primary-tumor-therapy-boost-trial-100598582",false,"NCT07073365","Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)","A Prospective Cohort Observational Study of Local Therapy for the Primary Tumor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer Following Osimertinib Plus Chemotherapy (FLAURA2 Regimen)","BOOST","\\\u003CInclusion Criteria\\>\n\nParticipants must meet all of the following criteria to be eligible:\n\n1. Age ≥ 20 years at the time of consent.\n2. Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).\n3. Presence of activating EGFR mutation (exon 19 deletion or L858R).\n4. Stage IV (metastatic) NSCLC at initial diagnosis.\n5. Completion of four cycles of first-line osimertinib plus platinum-based chemotherapy (FLAURA2 regimen).\n6. Radiologic evidence of disease control (complete response, partial response, or stable disease) after systemic therapy.\n7. Residual primary lung tumor suitable for local therapy (surgery or radiotherapy), as determined by multidisciplinary evaluation.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n9. Adequate organ function based on institutional laboratory criteria.\n10. Ability to understand and willingness to provide written informed consent.\n\n\\\u003CExclusion Criteria\\>\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Radiologic or clinical evidence of progressive disease during first-line osimertinib-chemotherapy.\n2. Extensive, unresectable metastatic disease not amenable to local therapy.\n3. Untreated or clinically unstable brain metastases.\n4. Known contraindications to surgery or radiotherapy.\n5. Active second malignancy requiring concurrent treatment.\n6. Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results.\n7. Pregnancy or breastfeeding at the time of enrollment.","ALL","20 Years",{"count":56,"type":57},70,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.",[63,64],"Non-Small Cell Lung Cancer","Epidermal Growth Factor Receptor",[63,66,67,68,69,70,71],"EGFR Mutation","FLAURA2","Osimertinib","Local Therapy","Surgery","Radiotherapy","2025-12-22",{"date":74,"type":75},"2025-12-30","ACTUAL",{"date":77,"type":75},"2025-07-01",{"date":79,"type":57},"2031-06-30",{"name":5,"class":6},1]